Safety and efficacy of tirofiban after early neurological deterioration in patients with branch atheromatous disease receiving alteplase.

ABSTRACT:

Objectives

No standard treatment exists for branch atheromatous disease (BAD), and patients' conditions often worsen after thrombolytic therapy. We evaluated the safety and effectiveness of tirofiban after early neurological deterioration (END) development in patients receiving intravenous alteplase.

Materials and methods

Bleeding incidence, National Institute of Health Stroke Scale (NIHSS) score, and modified Rankin scale (mRS) score were assessed for patients with BAD receiving alteplase within 4.5 h of stroke onset.

Results

Among 193 patients, 119 (61.64%) did not experience exacerbation after thrombolytic treatment, 74 (38.34%) had END, 34 were treated with tirofiban after END, and 40 received standard treatment. On day 7 or at discharge, no cases of symptomatic c

SUBMITTER: Zhong X 

PROVIDER: S-EPMC12802797 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature